ClinicalTrials.Veeva

Menu

A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

Novartis logo

Novartis

Status and phase

Completed
Phase 3

Conditions

Schizophrenia

Treatments

Drug: Clozapine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00250575
CLEX123J1301

Details and patient eligibility

About

Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

This study is not recruiting in the United States.

Full description

Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

Enrollment

43 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed as schizophrenia
  • Not responded to at least two atypical antipshychotics launched in Japan
  • Inpatient

Exclusion criteria

  • Low white blood cell count
  • Significant heart diseases
  • Diabetes mellitus

Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

43 participants in 1 patient group

1
Experimental group
Treatment:
Drug: Clozapine

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems